Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients

Blood Purification

Volumn 30, Issue 3, 2010, Pages 186-194

  Minutolo, Roberto ^a   Zamboli, Pasquale ^a   Chiodini, Paolo ^a   Mascia, Sara ^a   Vitiello, Santo ^a   Stanzione, Giovanna ^a   Bertino, Valerio ^a   Conte, Giuseppe ^a   De Nicola, Luca ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Anemia; CERA; Chronic kidney disease; Darbepoetin; Hemoglobin

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TRANSFERRIN;

ABDOMINAL PAIN; ACUTE PYELONEPHRITIS; ADULT; AGED; AMBULATORY CARE; ANGINA PECTORIS; ARTHRITIS; ARTICLE; BLEEDING; BLOOD PRESSURE MEASUREMENT; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; ERYTHROCYTE TRANSFUSION; FEMALE; FLU LIKE SYNDROME; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; INDUCED HYPOTENSION; IRON DEFICIENCY; KIDNEY DISEASE; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PERIPHERAL EDEMA; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RHINOPHARYNGITIS; SIDE EFFECT; STROKE; TREATMENT DURATION; TREATMENT PLANNING; URINARY TRACT INFECTION; VOMITING;

AGED; AGED, 80 AND OVER; ANEMIA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS;

EID: 77957311438     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321486     Document Type: Article

References (42)

1. Levin A, Djurdjev O, Duncan J, Rosenbaum D, Werb R: Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes. Nephrol Dial Transplant 2006;21:370-377.
2. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W: Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population. The ARIC Study. Kidney Int 2003;64:610-615.
3. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ: Kidney function and anemia as risk factors for coronary heart disease and mortality. The Atherosclerosis Risk in Communities (AR IC) Study. Am Heart J 2006;151:492-500. (Pubitemid 43144756)
4. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE: Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006;69:560-564.
5. Iseki K, Ikemiya Y, Iseki C, Takishita S: Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant 2003;18:899-905. (Pubitemid 36592530)
6. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD: Anemia and endstage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004;66:1131-1138.
7. Singh AK, Szczech L, Tang KL, et al: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
8. Pfeffer MA, Burdmann EA, Chen CY, et al, the TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
9. Singh AK: Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 2010;21:2-6.
10. Singh AK: Resolved: targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. J Am Soc Nephrol 2009;20:1436-1441.
11. Himmelfarb J, Szczech LA. Resolved: targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: con. J Am Soc Nephrol 2009;20:1441-1443.
12. Fishbane S, Besarab A: Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007;2:1274-1282.
13. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC: Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996;50:1255-1261.
14. Rodrigue ME, Moreau C, Lariviere R, Lebel M: Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin induced hypertension in uremic rats. J Cardiovasc Pharmacol 2003;41:388-395.
15. Barrett JD, Zhang Z, Zhu JH, et al: Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens 1998;16:1749-1757.
16. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87:5978-5982.
17. Stohlawetz PJ, Dzirlo L, Hergovich N, et al: Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983-2989.
18. Vaziri N: Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease? Nat Clin Pract Nephrol 2008;4:436-445.
19. Menne J, Park JK, Shushakova N, Mengel M, Meier M, Fliser D: The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol 2007;18:2046-2053.
20. Bahlmann FH, Song R, Boehm SM, et al: Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004;110:1006-1012.
21. Lipšic E, Westenbrink DB, van der Meer P, et al: Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008;10:22-29.
22. Besarab A, Flaharty KK, Erslev AJ, et al: Clinical pharmacology and economics of recombinant human erythropoietin in endstage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992;2:1405-1416.
23. Macdougall IC: Optimizing the use of erythropoietic agent-pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002;17(suppl 5):66-70.
24. Locatelli F, Reigner B: C. E. R. A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opin Investig Drugs 2007;16:1649-1661.
25. Szczech LA, Barnhart H, Inrig JK, et al: Secondary analysis of the CHOIR trial epoetinalpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-798.
26. U. S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
27. Fehr T, Ammann P, Garzoni D, et al: Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int 2004;66:1206-1211.
28. Drueke TB, Locatelli F, Clyne N, et al, CRE-ATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and a nemia. N Engl J Med 2006;355:2071-2084.
29. Locatelli F, Olivares J, Walker R, et al: Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741-747.
30. Ritz E, Laville M, Bilous RW, et al, on behalf of the ACORD Investigators and Coordinators. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the anemia correction in diabetes (ACORD) Study. Am J Kidney Dis 2007;49:194-207.
31. Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP: PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2003;18:89-100.
32. Macdougall IC, Walker R, Provenzano R, et al, on behalf of the ARCTOS study investigators: C. E. R. A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008;3:337-347.
33. De Nicola L, Conte G, Chiodini P, et al: Stability of target hemoglobin levels during the first year of epoetin treatment in CKD patients. Clin J Am Soc Nephrol 2007;2:938-946.
34. Minutolo R, Chiodini P, Cianciaruso B, et al: Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2009;4:552-559.
35. Hertel J E W, Locay HR, Scarlata DS, Prathikanti R, Audhya PK: Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease. Mayo Clin Proc 2006;81:1188-1194.
36. Locatelli F, Aljama P, Barany P, et al: European Best Practice Guidelines Working Group. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2):ii1-ii47.
37. Arneson TJ, Zaun D, Peng Y, Solid CA, Dunning S, Gilbertson DT: Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population. Nephrol Dial Transplant 2009;24:1378-1383.
38. Fliser D, Kleophas W, Dellana F, et al: Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C. E. R. A: the MIRACEL study. Curr Med Res Opin DOI: 10.1185/03007991003666652.
39. Provenzano R, Besarab A, Macdougall IC, et al, on behalf of the BA16528 Study Investigators: The continuous erythropoietin receptor activator (C. E. R. A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol 2007;67:306-317.
40. Kessler M, Martinez-Castelao A, Siamopoulos KC, et al: C. E. R. A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodial Int DOI: 10.1111/j.1542-4758.2009. 00421.x.
41. European Medicine Agency (EMEA): Product Information Mircera-H-C-739-IB- 21. Annex 1: Summary of product characteristics. http://www.ema.europa.eu/ humandocs/PDFs/EPAR/mircera/H-739-PI-en.pdf, accessed February 15, 2010.
42. Locatelli F, Mann JF, Aldigier JC, et al: C. E. R. A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol 2010;73:94-103.